Taigen Biopharmaceuticals Holdings (4157) reported revenue of NT$5.2 million for Oct 2026, +60.2% year on year and +66.6% from the previous month. Revenue for Jan–Oct 2026 was NT$37 million (+17.2% year on year).
Year-on-year revenue growth: 3 months in a row. →
In Oct 2026, it ranked No. 138 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$5.2 million | +60.2% | +66.6% |
| Sep 2026 | NT$3.2 million | +212.8% | -55.3% |
| Aug 2026 | NT$7.1 million | +172.2% | +138.6% |
| Jul 2026 | NT$3 million | -4.0% | -2.2% |
| Jun 2026 | NT$3 million | -7.1% | +3.4% |
| May 2026 | NT$2.9 million | -22.7% | +28.2% |
| Apr 2026 | NT$2.3 million | -37.8% | +57.6% |
| Mar 2026 | NT$1.4 million | -55.9% | -49.3% |
| Feb 2026 | NT$2.9 million | -15.5% | -52.7% |
| Jan 2026 | NT$6 million | +43.0% | -97.3% |
| Dec 2025 | NT$223.8 million | +6,482.8% | +5,327.1% |
| Nov 2025 | NT$4.1 million | +30.8% | +25.8% |
| Oct 2025 | NT$3.3 million | -16.7% | +225.4% |
| Sep 2025 | NT$1 million | -66.5% | -61.1% |
| Aug 2025 | NT$2.6 million | -17.1% | -15.8% |
| Jul 2025 | NT$3.1 million | +24.0% | -5.4% |
| Jun 2025 | NT$3.3 million | +51.9% | -14.0% |
| May 2025 | NT$3.8 million | -96.7% | +3.3% |
| Apr 2025 | NT$3.7 million | -24.0% | +11.7% |
| Mar 2025 | NT$3.3 million | +27.0% | -2.9% |
| Feb 2025 | NT$3.4 million | +34.5% | -20.1% |
| Jan 2025 | NT$4.2 million | -13.8% | +24.2% |
| Dec 2024 | NT$3.4 million | +15.8% | +7.8% |
| Nov 2024 | NT$3.2 million | +1.4% | -19.8% |
| Oct 2024 | NT$3.9 million | +54.5% | +31.1% |
Jan–Oct 2026 cumulative: NT$37 million (+17.2% YoY)
Other Biotech & Medical companies
Compare with peers: Taigen Biopharmaceuticals Holdings vs PEC / Taigen Biopharmaceuticals Holdings vs Lotus Pharm / Taigen Biopharmaceuticals Holdings vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
本月營收較去年同期增加,主要係因認列奈諾沙星授權至越南之里程碑款收入所致
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16